IMMUNOCHEMOTHERAPY OF METASTATIC MALIGNAN T-MELANOMA WITH EPIFOCAL DNCB AND SYSTEMIC DTIC

We describe an immunochemotherapy for metastatic melanoma that combine s epifocal applications of the contact sensitizer DNCB over cutaneous metastases with systemic DTIC treatment. 4 complete remissions and 3 p artial remissions were achieved in 15 patients. 6 of these remissions were seen in the 7 previously untreated patients. The advantages of th is therapy which is in particular interesting for dermatologists are t olerable side effects and low costs. This publication is designed to s timulate larger randomized trials in order to answer open questions.